Mecox CureMed

Mecox CureMed was a South Korean biopharmaceutical company focused on discovery and development of small-molecule drug candidates in oncology, neurology, inflammation, and related therapeutic areas. Publicly available third-party sources describe the company as a subsidiary or affiliate of Medicox and indicate a pipeline that included Tubulysin for solid tumors, Bozanics for orthopedic arthritis, Mecbentu for blood cancer, and internal code programs such as M-001, M-002, and M-003. The company appeared to operate clinical development activities in Korea and had previously used a U.S. subsidiary, Mecox Medi, to support North American clinical development. Multiple data providers now classify Mecox CureMed as closed, although historical business-partnering materials still describe it as an R&D-focused biopharmaceutical developer. Because primary company sources were not accessible and some secondary sources conflict on current operating status, several pipeline and corporate details should be treated as best-effort and partially unverified.